AlphaStocks
6.3
Consider Buy

Merck & Co., Inc. (MRK)

As of Sep 20, 2026, Merck & Co., Inc. (MRK) scores 6.3/10 on AlphaStocks' five-model composite, #37 of 168 Health Care stocks. At $147, MRK trades 34% below its model fair value of $221.

Health Care / Pharmaceuticals

S&P 500

$146.75

Middle of the pack. No strong signal either way.

Consider Buy

Score based on 5 of 5 models — high confidence

Data as of Sep 20, 2026

#37out of 168 in Health Care

Is Merck & Co., Inc. a Good Investment in 2026?

Merck & Co., Inc. (MRK) scores 6.3 out of 10 on AlphaStocks' composite model, earning a Consider Buy rating. The Greenblatt Magic Formula model rates Merck & Co., Inc. as Strong (Earnings yield 13.9% · ROC >100%). However, the Graham model rates it Caution — Significantly above fair value. Merck & Co., Inc. currently trades 34% below its estimated fair value of $221. Merck & Co., Inc. ranks #37 out of 168 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

P/E20.1ROE35.0Market Cap363BDiv Yield2.6

Estimated Fair Value

$220.9634% below

Trading below estimated fair value. ROE of 35% signals strong profitability. P/E of 20x is moderate for this quality level.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Neutral

4/9

Buffett

Attractive

Business quality & competitive moat

Graham

Caution

Significantly above fair value

Lynch

Neutral

PEG 4.3 · Slow Grower

Greenblatt

Strong

Earnings yield 13.9% · ROC >100%

Frequently Asked Questions

Is Merck & Co., Inc. (MRK) a good investment?
As of Sep 20, 2026, Merck & Co., Inc. (MRK) scores 6.3/10 on AlphaStocks' five-model composite, #37 of 168 Health Care stocks. At $147, MRK trades 34% below its model fair value of $221. That is a middle-of-the-pack score with no strong signal either way.
What is Merck & Co., Inc.'s Piotroski F-Score?
Merck & Co., Inc.'s Piotroski F-Score status is Neutral. The raw score is 4/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is MRK overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $221, MRK appears undervalued. The stock currently trades 34% below its estimated fair value. Trading below estimated fair value. ROE of 35% signals strong profitability. P/E of 20x is moderate for this quality level.
How does MRK compare to other Health Care stocks?
Merck & Co., Inc. ranks #37 out of 168 stocks in the Health Care sector, placing it in the top 22% of its sector by composite score. This is a strong position relative to sector peers.
What do investment models say about MRK?
AlphaStocks evaluates MRK using five proven investment models. Piotroski: Neutral; Buffett: Attractive; Graham: Caution; Lynch: Neutral; Greenblatt Magic Formula: Strong. These models are combined into a single composite score of 6.3/10.

Similar Stocks

AMPHLLYACAD

Compare MRK with

AMPH vs MRKLLY vs MRKACAD vs MRKMRK vs VALMRK vs PARR

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer